MARKET

BCRX

BCRX

Biocryst Pharmaceuticals Inc
NASDAQ
8.58
-0.17
-1.89%
Opening 09:37 05/21 EDT
OPEN
8.64
PREV CLOSE
8.74
HIGH
8.69
LOW
8.57
VOLUME
138.60K
TURNOVER
--
52 WEEK HIGH
11.31
52 WEEK LOW
6.00
MARKET CAP
2.18B
P/E (TTM)
-4.8269
1D
5D
1M
3M
1Y
5Y
1D
BioCryst Insider Makes a Six-Figure Move That Investors Can’t Ignore
TipRanks · 1d ago
BioCryst Earnings Call: ORLADEYO Momentum vs. Risks
TipRanks · 1d ago
BioCryst director Amy E. McKee sells 11,180 shares worth $100,284.6
PUBT · 1d ago
Weekly Report: what happened at BCRX last week (0511-0515)?
Weekly Report · 3d ago
European Navenibart Deal And Reaffirmed 2026 Outlook Could Be A Game Changer For BioCryst (BCRX)
Simply Wall St · 5d ago
BioCryst Chief Legal Officer Alane P. Barnes sells 62,500 shares for $596,250
PUBT · 5d ago
BioCryst’s Navenibart Deal And Pediatric Data Shape HAE Investment Case
Simply Wall St · 05/14 13:40
BioCryst Pharmaceuticals To Present New Real-World Evidence At The International Society For Pharmacoeconomics And Outcomes Research Conference, May 17–20
Benzinga · 05/13 11:15
More
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Its portfolio also includes navenibart, which is a late-stage, long-acting plasma kallikrein inhibitor. It has also obtained an early-stage program for atopic dermatitis, STAR0310.

Webull offers BioCryst Pharmaceuticals Inc stock information, including NASDAQ: BCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCRX stock methods without spending real money on the virtual paper trading platform.